Literature DB >> 15364804

Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice.

Anne Garnier1, Jennifer K Bendall, Sebastien Fuchs, Brigitte Escoubet, Francesca Rochais, Jacqueline Hoerter, Johnny Nehme, Marie-Lory Ambroisine, Noeleen De Angelis, Gilles Morineau, Pauline d'Estienne, Rodolphe Fischmeister, Christophe Heymes, Florence Pinet, Claude Delcayre.   

Abstract

BACKGROUND: Elevated circulating aldosterone level is associated with impaired cardiovascular function. Although the mechanisms are not fully understood, aldosterone antagonists decrease total and cardiovascular mortality in heart failure and myocardial infarction. Aldosterone induces cardiac fibrosis in experimental models, and it is synthesized locally in rat heart. These observations suggest pathological effects of aldosterone in heart that remain unclear. METHODS AND
RESULTS: Transgenic mice (TG) that overexpress the terminal enzyme of aldosterone biosynthesis, aldosterone synthase (AS), in heart have been raised by gene targeting with the alpha-myosin heavy chain promoter. AS mRNA increased 100-fold and aldosterone concentration 1.7-fold in hearts of male TG mice relative to wild-type. No structural or myocardial alterations were evidenced, because ventricle/body weight, AT1 and AT2 receptor binding, and collagen content were unchanged in TG. No alteration in cardiac function was evidenced by echocardiography, isolated perfused heart, or whole-cell patch clamp experiments. In contrast, coronary function was impaired, because basal coronary flow was decreased in isolated perfused heart (-55% of baseline values), and vasodilatation to acetylcholine, bradykinin, and sodium nitroprusside was decreased by 75%, 60%, and 75%, respectively, in TG mice compared with wild-type, showing that the defect was not related to NO production.
CONCLUSIONS: Increased cardiac aldosterone production in male mice induces a major coronary endothelium-independent dysfunction with no detectable alterations in cardiac structure and function. However, coronary dysfunction may be harmful for coronary adaptation to increased flow demand.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364804     DOI: 10.1161/01.CIR.0000142858.44680.27

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

Review 1.  Inhibition of the renin angiotensin system: implications for the endothelium.

Authors:  Carmine Savoia; Ernesto L Schiffrin
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

2.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

3.  Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?

Authors:  Sankar D Navaneethan; Emmanuel L Bravo
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 8.237

4.  [The role of aldosterone in hypertension].

Authors:  Oliver Vonend; Ivo Quack; Lars Christian Rump
Journal:  Wien Klin Wochenschr       Date:  2010-02       Impact factor: 1.704

Review 5.  Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 6.  Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.

Authors:  Miki Nagase; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2013-01-08       Impact factor: 28.314

Review 7.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

Review 8.  Aldosterone mediates cardiac fibrosis in the setting of hypertension.

Authors:  Feriel Azibani; Loubina Fazal; Christos Chatziantoniou; Jane-Lise Samuel; Claude Delcayre
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

Review 9.  Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism.

Authors:  Syamal K Bhattacharya; Malay S Gandhi; German Kamalov; Robert A Ahokas; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

Review 10.  Effects of biological sex on the pathophysiology of the heart.

Authors:  Loubina Fazal; Feriel Azibani; Nicolas Vodovar; Alain Cohen Solal; Claude Delcayre; Jane-Lise Samuel
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.